echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The Oncologist: Safety analysis of Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer: An update from the PALOMA series of 5-year follow-up comprehensive analysis

    The Oncologist: Safety analysis of Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer: An update from the PALOMA series of 5-year follow-up comprehensive analysis

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor, combined with endocrine (ET) approved for the treatment of hormone receptor positive (HR)/human epidermal growth factor receptor 2 negative (HER2−) Patients with advanced breast cancer (ABC).


    Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor, combined with endocrine (ET) approved for the treatment of hormone receptor positive (HR)/human epidermal growth factor receptor 2 negative (HER2−) Patients with advanced breast cancer (ABC).


    The article updates the comprehensive analysis of the 5-year follow-up safety of Palbociclib combined therapy in the PALOMA series of studies.


    The article updates the comprehensive analysis of the 5-year follow-up safety of Palbociclib combined therapy in the PALOMA series of studies.


    Comparison of treatment duration

    Comparison of treatment duration

    Palbociclib combined with endocrine group had any grade of neutropenia and infection were 82.


    Palbociclib combined with endocrine group had any grade of neutropenia and infection were 82.


    Adverse events of endocrine therapy

    Adverse events of endocrine therapy

    Adverse events related to combination or monotherapy

    Adverse events related to combination or monotherapy

    In summary, through a 5-year long-term comprehensive analysis, Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer is proved to be a safe treatment.


    In summary, through a 5-year long-term comprehensive analysis, Palbociclib combined with endocrine therapy for HR+/HER2-metastatic breast cancer is proved to be a safe treatment.


    ncbi.


    ncbi.
    nlm.
    nih.
    gov/?term=Finn+RS&cauthor_id=33486783">Richard S Finn,ncbi.
    nlm.
    nih.
    gov/?term=Rugo+HS&cauthor_id=33486783">Hope S Rugo,ncbi.
    nlm.
    nih.
    gov/?term=Gelmon+KA&cauthor_id=33486783">Karen A Gelmon , et al.
    Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up .
    .
    .
    5 to Years of the Follow-Up on May Oncologist 2021; 26 is (.
    5): e749-e755.
    doi: 10.
    1002 / onco.
    13684.
      ncbi.
    nlm.
    nih.
    gov/?term=Finn+RS&cauthor_id=33486783">Richard S Finn ncbi.
    nlm.
    nih.
    gov/?term=Rugo+HS&cauthor_id=33486783">Hope S Rugo ncbi.
    nlm.
    nih.
    gov/?term=Gelmon+KA&cauthor_id=33486783">Karen A Gelmon in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.